Nicolás Miguel Fissolo I am biochemist and PhD in human biology. Since 2008 I work as a researcher at the clinical neuroimmunology - Multiple Sclerosis Center of Catalonia (Cemcat) research group. My activity is based on the study of multiple sclerosis, mainly in the identification of molecular biomarkers associated to different aspects of the disease. Institutions of which they are part Main researcher Clinical Neuroimmunology Vall Hebron Institut de Recerca Investigador/a postdoctoral Multiple Sclerosis Centre of Catalonia LinkedIn Twitter Orcid Email Nicolás Miguel Fissolo LinkedIn Twitter Orcid Email Institutions of which they are part Main researcher Clinical Neuroimmunology Vall Hebron Institut de Recerca Investigador/a postdoctoral Multiple Sclerosis Centre of Catalonia I am biochemist and PhD in human biology. Since 2008 I work as a researcher at the clinical neuroimmunology - Multiple Sclerosis Center of Catalonia (Cemcat) research group. My activity is based on the study of multiple sclerosis, mainly in the identification of molecular biomarkers associated to different aspects of the disease.
I graduated as a biochemist in 1999 from the University of Córdoba (Argentina). In 2005 I obtained a PhD in human biology from the University of Ulm (Germany) for my work in the DNA vaccine field. Afterwards, I carried out a 3-year postdoctoral stay at the Hertie Institut for Brain Research at the University of Tübingen (Germany) focused on the study of antigenic presentation in multiple sclerosis. In 2008 I joined the research group of the clinical neuroimmunology - Cemcat directed by Dr. Xavier Montalban where I have been working until now. Since 2010 I have been working as principal investigator of several projects focused on the identification of new molecular biomarkers that allow the characterization of the different aspects of the disease, among which are included prognostic biomarkers in the initial phases of the disease, biomarkers of response to treatment, and biomarkers of disease activity.
Projects Identificación de proteínas relacionadas con el envejecimiento en pacientes con esclerosis múltiple progresiva y estudio de su potencial efecto neuroreparador en modelos animales. IP: Nicolás Miguel Fissolo Collaborators: Luciana Midaglia Fernandez Funding agency: Instituto de Salud Carlos III Funding: 102850 Reference: PI17/00596 Duration: 01/01/2018 - 30/06/2022 Neuroimmunologia Clínica. Centre d'Esclerosi Múltiple de Catalunya (CEMCAT( (GRC) IP: Neuroimmunologia Clínica. Centre d'Esclerosi Múltiple de Catalunya (CEMCAT( (GRC) Collaborators: Susana Otero Romero, Carlos Nos Llopis, Neuroimmunologia Clínica. Centre d'Esclerosi Múltiple de Catalunya (CEMCAT( (GRC), José Ant. Graells Salvador, Jaume Sastre Garriga, Jordi Rio Izquierdo, Ingrid Galán Cartaña, Rosalia Horno Ocaña, Manuel Comabella Lopez, Margarida Capell Maymo, Carmen Tur Gomez, Jordi Barquinero Mañez, Herena Eixarch Ahufinger, Carme Santoyo Medina, Oriol Nualart Mundo, Mar Tintore Subirana, M Jesus Arevalo Navines, Dunia Muñoz Valdivielso, Carmen Espejo Ruiz, Silvia Casacuberta Serra, Sergio Vergara Ruiz, Luciana Midaglia Fernandez, Joaquin Castillo Justribo, Milagros Fraga Pereira, Breogan Rodriguez Acevedo, Mireia Castillo Juarez, Nicolás Miguel Fissolo , Georgina Arrambide García Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 50000 Reference: 2014 SGR 1082 Duration: 01/01/2014 - 31/12/2016 Red Española de Esclerosis Múltiple IP: Red Española de Esclerosis Múltiple Collaborators: Susana Otero Romero, Carlos Nos Llopis, Red Española de Esclerosis Múltiple, Jaume Sastre Garriga, Jordi Rio Izquierdo, Fco. Javier Aymerich Martínez, Ingrid Galán Cartaña, Rosalia Horno Ocaña, Manuel Comabella Lopez, Carmen Tur Gomez, Cristina Auger Acosta, Herena Eixarch Ahufinger, Montserrat Moreno Sánchez, Alex Rovira Cañellas, Mar Tintore Subirana, M Jesus Arevalo Navines, Carmen Espejo Ruiz, Angela Vidal Jordana, Joaquin Castillo Justribo, Mireia Castillo Juarez, Nicolás Miguel Fissolo Funding agency: Instituto de Salud Carlos III Funding: 198090 Reference: RD12/0032/0017 Duration: 01/01/2013 - 31/12/2016 Immunogenicity: assesing the clinical relevance and risk minimization of antibodies to biopharmaceuticals. IMI Grant Agreement nº 115303 IP: Manuel Comabella Lopez Collaborators: Carmen Tur Gomez, Immunogenicity: assesing the clinical relevance and risk minimization of antibodies to biopharmaceuticals. IMI Grant Agreemen, Nicolás Miguel Fissolo Funding agency: The Innovative Medicines Initiative Funding: 464328 Reference: ABIRISK_IMI2010 Duration: 01/03/2012 - 27/02/2018 Pagination First page « Previous page ‹ Page 1 Current page 2 Page 3 Next page › Last page »
